GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Kangtai Biological Products Co Ltd (SZSE:300601) » Definitions » EBIT

Shenzhen Kangtai Biological Products Co (SZSE:300601) EBIT : ¥883 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Shenzhen Kangtai Biological Products Co EBIT?

Shenzhen Kangtai Biological Products Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥98 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥883 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shenzhen Kangtai Biological Products Co's annualized ROC % for the quarter that ended in Mar. 2024 was 2.52%. Shenzhen Kangtai Biological Products Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5.41%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shenzhen Kangtai Biological Products Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.06%.


Shenzhen Kangtai Biological Products Co EBIT Historical Data

The historical data trend for Shenzhen Kangtai Biological Products Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Kangtai Biological Products Co EBIT Chart

Shenzhen Kangtai Biological Products Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 672.38 774.75 1,493.76 -229.27 1,054.03

Shenzhen Kangtai Biological Products Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 269.30 349.97 229.62 205.15 97.94

Competitive Comparison of Shenzhen Kangtai Biological Products Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Kangtai Biological Products Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Kangtai Biological Products Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Kangtai Biological Products Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shenzhen Kangtai Biological Products Co's EV-to-EBIT falls into.



Shenzhen Kangtai Biological Products Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥883 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhen Kangtai Biological Products Co  (SZSE:300601) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shenzhen Kangtai Biological Products Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=346.72 * ( 1 - 17.08% )/( (11160.412 + 11651.228)/ 2 )
=287.500224/11405.82
=2.52 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15085.359 - 2629.35 - ( 1295.597 - max(0, 2751.351 - 5396.004+1295.597))
=11160.412

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15020.723 - 2372.534 - ( 996.961 - max(0, 2745.483 - 4994.531+996.961))
=11651.228

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Shenzhen Kangtai Biological Products Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=391.744/( ( (5715.985 + max(1432.325, 0)) + (5730.098 + max(1591.96, 0)) )/ 2 )
=391.744/( ( 7148.31 + 7322.058 )/ 2 )
=391.744/7235.184
=5.41 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2787.608 + 772.854 + 530.85) - (2629.35 + 0 + 29.637)
=1432.325

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2715.699 + 896.004 + 376.312) - (2372.534 + 0 + 23.521)
=1591.96

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shenzhen Kangtai Biological Products Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=882.669/21740.018
=4.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhen Kangtai Biological Products Co EBIT Related Terms

Thank you for viewing the detailed overview of Shenzhen Kangtai Biological Products Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Kangtai Biological Products Co (SZSE:300601) Business Description

Traded in Other Exchanges
N/A
Address
No. 6 Kefa Road, Science and Technology Industrial Park, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.
Executives
Liu Jian Kai Directors, executives
Tao Jin Secretary Dong
Zheng Hai Fa Directors, executives
Zhou Hui Executives
Miao Xiang Directors, executives
Wen Fei Dong Director
Du Wei Min Directors, executives
Lv Zhi Yun Supervisors
Gan Jian Hui Executives
Zhu Zheng Yu Executives
Liu Qun Executives
Li Tong Executives
Yuan Li Ping Director
Li Xiang Ming Independent director

Shenzhen Kangtai Biological Products Co (SZSE:300601) Headlines

No Headlines